Aude Fléchon
A5001456598- Bladder and Urothelial Cancer Treatments
- Testicular diseases and treatments
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Neuroblastoma Research and Treatments
- Urologic and reproductive health conditions
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- PARP inhibition in cancer therapy
- Cancer Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Sexual Differentiation and Disorders
- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Glioma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
Centre Léon Bérard
2016-2025
Centre de Recherche en Cancérologie de Lyon
2009-2025
Lymphoma Study Association
2018-2024
Université Claude Bernard Lyon 1
2008-2023
Hôpital Lyon Sud
2016-2020
Hospices Civils de Lyon
2016-2020
Centre François Baclesse
2019
University of St. Gallen
2017
St Olav's University Hospital
2017
Centre Oscar Lambret
2011-2015
Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival men with castration-resistant prostate cancer after chemotherapy.In our phase 3, double-blind, placebo-controlled trial, we stratified 1199 chemotherapy according Eastern Cooperative Oncology Group performance-status score and pain intensity. randomly assigned them, a 2:1 ratio, receive...
Biosynthesis of extragonadal androgen may contribute to the progression castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor biosynthesis, prolongs overall survival among patients with metastatic cancer who have received chemotherapy.We randomly assigned, in a 2:1 ratio, 1195 had previously docetaxel receive 5 mg prednisone twice daily either 1000 acetate (797 patients) or placebo (398 patients). The primary end point was survival. secondary points...
Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% a median overall survival (OS) 7-8 months. Sacituzumab govitecan (SG) is TROP-2-directed antibody-drug conjugate an SN-38 payload has shown preliminary activity in mUC.
No treatment has surpassed platinum-based chemotherapy in improving overall survival patients with previously untreated locally advanced or metastatic urothelial carcinoma. Download a PDF of the Research Summary. We conducted phase 3, global, open-label, randomized trial to compare efficacy and safety enfortumab vedotin pembrolizumab Patients were randomly assigned 1:1 ratio receive 3-week cycles (at dose 1.25 mg per kilogram body weight intravenously on days 1 8) 200 day 1) (enfortumab...
In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference followed similar meetings 2003 (Essen, Germany) 2006 (Amsterdam, The Netherlands) [Schmoll H-J, Souchon R, Krege S et al. consensus diagnosis treatment germ-cell cancer: a report Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399; S, Beyer J, R second meeting group (EGCCCG): part I. Eur Urol 2008; 53: 478-496; II. 497-513]. A panel 56 60...
To develop a prognostic model in patients with germ cell tumors (GCT) who experience treatment failure cisplatin-based first-line chemotherapy.Data from 1,984 GCT progressed after at least three cycles and were treated conventional-dose or carboplatin-based high-dose salvage chemotherapy was retrospectively collected 38 centers/groups worldwide. One thousand five hundred ninety-four (80%) of eligible randomly divided into training set 1,067 (67%) validation 527 (33%). Seminomas aside for...
Purpose Conventional-dose chemotherapy (CDCT) and high-dose (HDCT) may both be successfully used as salvage treatment for patients with metastatic germ cell tumors (GCTs) who experience progression first-line treatment. Patients Methods Data on 1,984 GCTs experienced after at least three cisplatin-based cycles were treated either CDCT or carboplatin-based HDCT collected from 38 centers groups worldwide. Of patients, 1,594 (80%) eligible, among the eligible 1,435 (90%) could reliably...
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including
The optimal perioperative chemotherapy regimen for patients with nonmetastatic muscle-invasive bladder cancer is not defined.Between February 2013 and March 2018, 500 were randomly assigned in 28 French centers received either six cycles of dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (dd-MVAC) once every 2 weeks or four gemcitabine (GC) 3 before surgery (neoadjuvant group) after (adjuvant group). We report the primary end point GETUG-AFU V05 VESPER trial (ClinicalTrials.gov...
LBA5000 Background: PEACE-1 demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) radiographic progression-free-survival (rPFS) in men de novo mCSPC. The present analysis examines the second pre-planned primary endpoint of low-volume population: impact prostate irradiation (RT) receiving intensified systemic treatment. Methods: is an academic, multicentre, international, 2x2 design, phase 3 trial. co-primary endpoints...